These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
352 related articles for article (PubMed ID: 16540668)
1. Levels of HdmX expression dictate the sensitivity of normal and transformed cells to Nutlin-3. Patton JT; Mayo LD; Singhi AD; Gudkov AV; Stark GR; Jackson MW Cancer Res; 2006 Mar; 66(6):3169-76. PubMed ID: 16540668 [TBL] [Abstract][Full Text] [Related]
2. HDM2 antagonist Nutlin-3 disrupts p73-HDM2 binding and enhances p73 function. Lau LM; Nugent JK; Zhao X; Irwin MS Oncogene; 2008 Feb; 27(7):997-1003. PubMed ID: 17700533 [TBL] [Abstract][Full Text] [Related]
3. Hdmx modulates the outcome of p53 activation in human tumor cells. Wade M; Wong ET; Tang M; Stommel JM; Wahl GM J Biol Chem; 2006 Nov; 281(44):33036-44. PubMed ID: 16905769 [TBL] [Abstract][Full Text] [Related]
4. p53 promotes its own polyubiquitination by enhancing the HDM2 and HDMX interaction. Medina-Medina I; Martínez-Sánchez M; Hernández-Monge J; Fahraeus R; Muller P; Olivares-Illana V Protein Sci; 2018 May; 27(5):976-986. PubMed ID: 29524278 [TBL] [Abstract][Full Text] [Related]
5. Identification of an aberrantly spliced form of HDMX in human tumors: a new mechanism for HDM2 stabilization. Giglio S; Mancini F; Gentiletti F; Sparaco G; Felicioni L; Barassi F; Martella C; Prodosmo A; Iacovelli S; Buttitta F; Farsetti A; Soddu S; Marchetti A; Sacchi A; Pontecorvi A; Moretti F Cancer Res; 2005 Nov; 65(21):9687-94. PubMed ID: 16266988 [TBL] [Abstract][Full Text] [Related]
6. BH3 activation blocks Hdmx suppression of apoptosis and cooperates with Nutlin to induce cell death. Wade M; Rodewald LW; Espinosa JM; Wahl GM Cell Cycle; 2008 Jul; 7(13):1973-82. PubMed ID: 18604177 [TBL] [Abstract][Full Text] [Related]
7. Alterations in gene expression and sensitivity to genotoxic stress following HdmX or Hdm2 knockdown in human tumor cells harboring wild-type p53. Heminger K; Markey M; Mpagi M; Berberich SJ Aging (Albany NY); 2009 Jan; 1(1):89-108. PubMed ID: 19946469 [TBL] [Abstract][Full Text] [Related]
9. HdmX stimulates Hdm2-mediated ubiquitination and degradation of p53. Linares LK; Hengstermann A; Ciechanover A; Müller S; Scheffner M Proc Natl Acad Sci U S A; 2003 Oct; 100(21):12009-14. PubMed ID: 14507994 [TBL] [Abstract][Full Text] [Related]
10. HDM2 and HDMX Proteins in Human Cancer. Hároníková L; Vojtěšek B Klin Onkol; 2018; 31(Suppl 2):63-70. PubMed ID: 31023026 [TBL] [Abstract][Full Text] [Related]
11. HDMX-L is expressed from a functional p53-responsive promoter in the first intron of the HDMX gene and participates in an autoregulatory feedback loop to control p53 activity. Phillips A; Teunisse A; Lam S; Lodder K; Darley M; Emaduddin M; Wolf A; Richter J; de Lange J; Verlaan-de Vries M; Lenos K; Böhnke A; Bartel F; Blaydes JP; Jochemsen AG J Biol Chem; 2010 Sep; 285(38):29111-27. PubMed ID: 20659896 [TBL] [Abstract][Full Text] [Related]
12. E2F-1 transcriptional activity is a critical determinant of Mdm2 antagonist-induced apoptosis in human tumor cell lines. Kitagawa M; Aonuma M; Lee SH; Fukutake S; McCormick F Oncogene; 2008 Sep; 27(40):5303-14. PubMed ID: 18521084 [TBL] [Abstract][Full Text] [Related]
14. Elevated MDM2 boosts the apoptotic activity of p53-MDM2 binding inhibitors by facilitating MDMX degradation. Xia M; Knezevic D; Tovar C; Huang B; Heimbrook DC; Vassilev LT Cell Cycle; 2008 Jun; 7(11):1604-12. PubMed ID: 18520179 [TBL] [Abstract][Full Text] [Related]
15. Histone deacetylase inhibitors enhance the anticancer activity of nutlin-3 and induce p53 hyperacetylation and downregulation of MDM2 and MDM4 gene expression. Palani CD; Beck JF; Sonnemann J Invest New Drugs; 2012 Feb; 30(1):25-36. PubMed ID: 20680659 [TBL] [Abstract][Full Text] [Related]
16. Restoration of p53 pathway by nutlin-3 induces cell cycle arrest and apoptosis in human rhabdomyosarcoma cells. Miyachi M; Kakazu N; Yagyu S; Katsumi Y; Tsubai-Shimizu S; Kikuchi K; Tsuchiya K; Iehara T; Hosoi H Clin Cancer Res; 2009 Jun; 15(12):4077-84. PubMed ID: 19509161 [TBL] [Abstract][Full Text] [Related]
17. Identification of a Small Molecule That Overcomes HdmX-Mediated Suppression of p53. Karan G; Wang H; Chakrabarti A; Karan S; Liu Z; Xia Z; Gundluru M; Moreton S; Saunthararajah Y; Jackson MW; Agarwal MK; Wald DN Mol Cancer Ther; 2016 Apr; 15(4):574-582. PubMed ID: 26883273 [TBL] [Abstract][Full Text] [Related]
18. Nutlin-3, an Hdm2 antagonist, inhibits tumor adaptation to hypoxia by stimulating the FIH-mediated inactivation of HIF-1alpha. Lee YM; Lim JH; Chun YS; Moon HE; Lee MK; Huang LE; Park JW Carcinogenesis; 2009 Oct; 30(10):1768-75. PubMed ID: 19696166 [TBL] [Abstract][Full Text] [Related]
19. Nutlin-3, a small-molecule MDM2 inhibitor, sensitizes Caki cells to TRAIL-induced apoptosis through p53-mediated PUMA upregulation and ROS-mediated DR5 upregulation. Park EJ; Choi KS; Yoo YH; Kwon TK Anticancer Drugs; 2013 Mar; 24(3):260-9. PubMed ID: 23187459 [TBL] [Abstract][Full Text] [Related]
20. Hdm2 disrupts HdmX-mediated nuclear export of p53 by sequestering it in nucleus. Ni Y; Chen H; Cheng X; Sun B; Wu Z; Zhan Q; Zhuang Z Exp Cell Res; 2024 Aug; 441(2):114185. PubMed ID: 39069150 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]